全文获取类型
收费全文 | 37篇 |
免费 | 2篇 |
专业分类
基础医学 | 2篇 |
口腔科学 | 1篇 |
临床医学 | 3篇 |
内科学 | 11篇 |
皮肤病学 | 1篇 |
神经病学 | 3篇 |
外科学 | 8篇 |
预防医学 | 1篇 |
眼科学 | 2篇 |
药学 | 6篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 2篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2015年 | 1篇 |
2014年 | 1篇 |
2013年 | 4篇 |
2012年 | 3篇 |
2011年 | 4篇 |
2010年 | 1篇 |
2009年 | 2篇 |
2008年 | 1篇 |
2006年 | 1篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2000年 | 1篇 |
1990年 | 1篇 |
排序方式: 共有39条查询结果,搜索用时 156 毫秒
1.
2.
3.
Hakkou J Rostom S Aissaoui N Berrada Ghezioul K Bahiri R Abouqal R Hajjaj-Hassouni N 《Clinical rheumatology》2012,31(3):441-445
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is the most widely used instrument for the assessment of disease
activity in ankylosing spondylitis (AS). Objective. The aims to investigate whether the alternative BASDAI, here termed as the miniBASDAI [(Question (Q) 1 fatigue + Q2 spinal
pain) + mean of (Q5 strength morning stiffness + Q6 duration morning stiffness)] / 3], measures disease activity more accurately
in the subgroup of AS patients without peripheral manifestations. One hundred and ten patients were included in this cross-sectional
study according to the modified New York criteria for AS. Clinical and biological parameters were evaluated. The disease activity
was evaluated by the BASDAI. We calculated the miniBASDAI by omitting both the peripheral joints and the enthesitis questions:
questions 3 and 4. Patients were dichotomized into a “P+” group if peripheral manifestations were present (at least arthritis
or enthesitis) and a “P−” group, the subgroup without peripheral involvement (with either arthritis or enthesitis). Correlation
of the BASDAI and miniBASDAI with other disease parameters were examined with the Spearman's rank correlation analysis. One
hundred and ten patients were recruited. The percentage of patients with pure axial disease manifestation without peripheral
involvement “P − group” was 42.7%. We found a similarly good correlation of the miniBASDAI with patient global, physician
on disease activity, BASFI, ESR and CRP if compared to the correlation of the original BASDAI with these disease parameters,
also in the group without peripheral involvement. Our study suggests that the BASDAI remains valid in assessing disease activity
in AS patients with and without peripheral manifestations. 相似文献
4.
5.
Background: Silodosin is a new α1-adrenergic receptor antagonist that is selective for the α1A-adrenergic receptor. It was approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).Objective: This article reviews the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of silodosin in adult male patients with BPH.Methods: A search of MEDLINE (1950–October 8, 2009), International Pharmaceutical Abstracts (1970–October 8, 2009), and the Iowa Drug Information Service database (1966–October 8, 2009) was conducted using the terms silodosin, KMD-3213, benign prostatic hyperplasia, and α1-adrenergic receptor antagonist. Reports of research and review articles published in English were identified and evaluated, and the bibliographies of these articles were reviewed for additional relevant publications. A search of the FDA Web site was performed, and abstracts and posters presented at scientific meetings of the American Urological Association were reviewed.Results: By antagonizing α1A-adrenergic receptors in the prostate and urethra, silodosin causes smooth muscle relaxation in the LUT. Silodosin has greater affinity for the α1A-adrenergic receptor than for the α1B-adrenergic receptor (by a factor of 583), minimizing the propensity for blood pressure-related adverse effects mediated by α1B blockade. In 3 controlled clinical studies in patients with BPH-related LUTS (1 published; 2 presented in the prescribing information and published in a pooled analysis), patients receiving silodosin at a total daily dose of 8 mg had significant improvements in the International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax) compared with those receiving placebo (both, P < 0.05). The most commonly reported adverse effect was abnormal or retrograde ejaculation (>22%), and the incidence of orthostatic hypotension was low (<3%).Conclusions: In the small number of clinical trials reviewed, silodosin was associated with significant reductions in IPSS and Qmax compared with placebo. To determine whether silodosin's selectivity for the α1A-adrenergic receptor translates into a clinical advantage relative to other available agents, long-term studies evaluating the comparative efficacy and tolerability of silodosin and other α1-blockers (specifically tamsulosin) are necessary. 相似文献
6.
Pro-inflammatory and pro-apoptotic mediators have been involved in the pathogenesis of neurodegenerative diseases. Tigecycline (Tig), a glycylcycline antibiotic and an analog of Minocycline, is shown to exert anti-inflammatory effects that are distinct from its anti-microbial activity. Its neuroprotective mechanism is unknown. In this study, we investigated the direct protective mechanisms of tigecycline against lipopolysaccharide (LPS)-induced Rat pheochromocytoma (PC12) cells. The results showed that tigecycline significantly attenuated the expression and the release of nuclear factor-kappa beta (NF-κB), tumor necrosis factor-alpha (TNF-α) and interleukin-1beta (IL-1β), as well as nitric oxide (NO) levels in LPS-induced PC12 cells. In addition, tigecycline dose-dependently decreased cytochrome c release and caspase-3 activity. This later finding corroborated the results of decreased pro-apoptotic Bad, and increased anti-apoptotic Bcl-2 protein expression thus, confirming a neuroprotective effect of the drug in differentiated PC12 cells induced with LPS. The findings of our study suggest new targets for tigecycline and support the potential for tigecycline to be investigated as a therapeutic agent for neurodegenerative disorders. 相似文献
7.
Bennis A Ridai M Nafidi S Soulami S Tahiri A Chraibi N 《Archives des maladies du coeur et des vaisseaux》2000,93(4):381-384
The authors report two cases of Recklinghausen's disease admitted for cardiac tamponade. Two-dimensional echocardiography showed a pericardial tumour in addition to a compressive pericardial effusion. After pericardial drainage, the outcome was rapidly fatal. Histological examination confirmed the diagnosis of a malignant intrapericardial schwannoma. A review of the literature revealed the scarcity of mediastinal malignant schwannoma. Associated with Von Reckinghausen's disease in 2 to 13% of cases, the prognosis is poor. The presentation of malignant mediastinal schwannoma with cardiac tamponade remains very rare. 相似文献
8.
Benyounès Ramdani Mohamed Zamd Khadija Hachim Kenza Soulami Madiha Ezzahidy Malika Souiri Wafaa Fadili Assia Lahboub Leila Hanafi Meryem Boujida Saida Squalli Amal Benkirane Mohamed Gharbi Benghanem Ghizlane Medkouri 《Néphrologie & thérapeutique》2012,8(4):247-258
Acute postinfectious glomerulonephritis are defined by an acute nonsuppurative inflammatory insult predominantly glomerular. Its current incidence is uncertain because of the frequency of subclinical forms. The most common infectious agent involved is beta hemolytic streptococcus group A. Acute postinfectious glomerulonephritis is uncommon in adults, and its incidence is progressively declining in developed countries. Humoral immunity plays a key role in the pathogenesis of kidney damage. Complement activation by the alternative pathway is the dominant mechanism, but a third way (lectin pathway) has been recently identified. The classic clinical presentation is sudden onset of acute nephritic syndrome after a free interval from a streptococcal infection. Treatment is essentially symptomatic and prevention is possible through improved hygiene and early treatment of infections. 相似文献
9.
10.